Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Pfeffer, U. Uveal Melanoma. Cancers 2019, 11, 1986. [Google Scholar] [CrossRef] [Green Version]
- Carvajal, R.D.; Schwartz, G.K.; Tezel, T.; Marr, B.; Francis, J.H.; Nathan, P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br. J. Ophthalmol. 2016, 101, 38–44. [Google Scholar] [CrossRef] [Green Version]
- Krantz, B.; Dave, N.; Komatsubara, K.M.; Marr, B.P.; Carvajal, R.D. Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin. Ophthalmol. 2017, 11, 279–289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, M.; Durairaj, P.; Yeung, J. Uveal Melanoma: A Review of the Literature. Oncol. Ther. 2018, 6, 87–104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rodriguez-Vidal, C.; Fernandez-Diaz, D.; Fernandez-Marta, B.; Lago-Baameiro, N.; Pardo, M.; Silva, P.; Paniagua, L.; Blanco-Teijeiro, M.J.; Piñeiro, A.; Bande, M. Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers 2020, 12, 2557. [Google Scholar] [CrossRef] [PubMed]
- Schank, T.E.; Hassel, J.C. Immunotherapies for the Treatment of Uveal Melanoma—History and Future. Cancers 2019, 11, 1048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ponti, A.; Denys, A.; Digklia, A.; Schaefer, N.; Hocquelet, A.; Knebel, J.-F.; Michielin, O.; Dromain, C.; Duran, R. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J. Nucl. Med. 2019, 61, 350–356. [Google Scholar] [CrossRef]
- Reichstein, D.A.; Brock, A.L. Radiation therapy for uveal melanoma: A review of treatment methods available in 2021. Curr. Opin. Ophthalmol. 2021, 32, 183–190. [Google Scholar] [CrossRef] [PubMed]
- Tura, A.; Merz, H.; Reinsberg, M.; Lüke, M.; Jager, M.J.; Grisanti, S.; Lüke, J. Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res. 2016, 29, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Tura, A.; Lüke, J.; Merz, H.; Reinsberg, M.; Lüke, M.; Jager, M.J.; Grisanti, S. Identification of Circulating Melanoma Cells in Uveal Melanoma Patients by Dual-Marker Immunoenrichment. Investig. Opthalmol. Vis. Sci. 2014, 55, 4395–4404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schuster, R.; Bechrakis, N.E.; Stroux, A.; Busse, A.; Schmittel, A.; Thiel, E.; Foerster, M.H.; Keilholz, U. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology 2011, 80, 57–62. [Google Scholar] [CrossRef]
- Schuster, R.; Bechrakis, N.E.; Stroux, A.; Busse, A.; Schmittel, A.; Scheibenbogen, C.; Thiel, E.; Foerster, M.H.; Keilholz, U. Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma. Clin. Cancer Res. 2007, 13, 1171–1178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nichols, E.E.; Richmond, A.; Daniels, A.B. Micrometastatic dormancy in uveal melanoma: A comprehensive review of the evidence, mechanisms, and implications for future adjuvant therapies. Int. Ophthalmol. Clin. 2017, 57, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Pereira, P.R.; Odashiro, A.N.; Lim, L.A.; Miyamoto, C.; Blanco, P.L.; Odashiro, M.; Maloney, S.; De Souza, D.F.; Burnier, M.N. Current and emerging treatment options for uveal melanoma. Clin. Ophthalmol. 2013, 7, 1669–1682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maio, M.; Danielli, R.; Chiarion-Sileni, V.; Pigozzo, J.; Parmiani, G.; Ridolfi, R.; De Rosa, F.; Del Vecchio, M.; Di Guardo, L.; Queirolo, P.; et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann. Oncol. 2013, 24, 2911–2915. [Google Scholar] [CrossRef]
- Rodriguez, J.M.P.; De Olza, M.O.; Codes, M.; Lopez-Martin, J.A.; Berrocal, A.; García, M.; Gurpide, A.; Homet, B.; Martin-Algarra, S. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. J. Clin. Oncol. 2014, 32, 9033. [Google Scholar] [CrossRef]
- Zimmer, L.; Vaubel, J.; Mohr, P.; Hauschild, A.; Utikal, J.; Simon, J.; Garbe, C.; Herbst, R.; Enk, A.; Kämpgen, E.; et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS ONE 2015, 10, e0118564. [Google Scholar] [CrossRef] [PubMed]
- Kottschade, L.A.; McWilliams, R.R.; Markovic, S.N.; Block, M.S.; Villasboas Bisneto, J.; Pham, A.Q.; Esplin, B.L.; Dronca, R.S. The use of pembrolizumab for the treatment of metastatic uveal melanoma. J. Clin. Oncol. 2015, 33, 300–303. [Google Scholar] [CrossRef]
- Carvajal, R.D.; Sosman, J.A.; Quevedo, J.F.; Milhem, M.M.; Joshua, A.M.; Kudchadkar, R.R.; Linette, G.P.; Gajewski, T.F.; Lutzky, J.; Lawson, D.H.; et al. Effect of selumetinib vs. chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial. JAMA 2014, 311, 2397–2405. [Google Scholar] [CrossRef] [PubMed]
- Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E. SUMIT: Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Selumetinib in Combination with Dacarbazine in Patients with Metastatic Uveal Melanoma; Society for Melanoma Research Congress: San Francisco, CA, USA, 2015. [Google Scholar]
- Falchook, G.S.; Lewis, K.D.; Infante, J.R.; Gordon, M.S.; Vogelzang, N.J.; DeMarini, D.J.; Sun, P.; Moy, C.; A Szabo, S.; Roadcap, L.T.; et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 782–789. [Google Scholar] [CrossRef] [Green Version]
- Saraiva, V.S.; Caissie, A.L.; Segal, L.; Edelstein, C.; Burnier, M.N. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res. 2005, 15, 245–250. [Google Scholar] [CrossRef]
- Ambrosini, G.; Musi, E.; Ho, A.L.; De Stanchina, E.; Schwartz, G.K. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol. Cancer Ther. 2013, 12, 768–776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, J.; Nagasawa, S. Immunostimulatory effects of radiotherapy for local and systemic control of melanoma: A review. Int. J. Mol. Sci. 2021, 21, 1–23. [Google Scholar]
- Krishna, Y.; McCarthy, C.; Kalirai, H.; Coupland, S.E. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum. Pathol. 2017, 66, 159–166. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.; Elsayed, M.; Lawson, D.; Ermentrout, R.; Kudchadkar, R.; Bercu, Z.; Yushak, M.; Newsome, J.; Kokabi, N. 03:18 PM Abstract No. 230 Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization: A 15-year single-institution experience. J. Vasc. Interv. Radiol. 2019, 30, S103. [Google Scholar] [CrossRef] [Green Version]
- Ruohoniemi, D.M.; Zhan, C.; Wei, J.; Kulkarni, K.; Aaltonen, E.T.; Horn, J.C.; Hickey, R.M.; Taslakian, B. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. J. Vasc. Interv. Radiol. 2020, 31, 1233–1241. [Google Scholar] [CrossRef] [PubMed]
- Zheng, J.; Irani, Z.; Lawrence, D.; Flaherty, K.; Arellano, R.S. Combined Effects of Yttrium-90 Transarterial Radio-embolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. J. Vasc. Interv. Radiol. 2018, 29, 1369–1375. [Google Scholar] [CrossRef] [PubMed]
- Arulananda, S.; Parakh, S.; Palmer, J.; Goodwin, M.; Andrews, M.C.; Cebon, J. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep. 2019, 2, 1–6. [Google Scholar] [CrossRef]
- Schelhorn, J.; Richly, H.; Ruhlmann, M.; Lauenstein, T.C.; Theysohn, J.M. A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol. 2015, 4, 204798161557041. [Google Scholar] [CrossRef] [PubMed]
- Williamson, C.W.; Sherer, M.V.; Zamarin, D.; Sharabi, A.B.; Dyer, B.A.; Mell, L.K.; Mayadev, J.S. Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer 2021, 127, 1–15. [Google Scholar] [CrossRef]
- Eaton, B.R.; Kim, H.S.; Schreibmann, E.; Schuster, D.M.; Galt, J.R.; Barron, B.; Kim, S.; Liu, Y.; Landry, J.; Fox, T. Quantitative dosimetry for yttrium-90 radionuclide therapy: Tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. J. Vasc. Interv. Radiol. 2014, 25, 288–295. [Google Scholar] [CrossRef]
- Filippi, L.; Scopinaro, F.; Pelle, G.; Cianni, R.; Salvatori, R.; Schillaci, O.; Bagni, O. Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 432–440. [Google Scholar] [CrossRef] [PubMed]
- Leppelmann, K.S.; Mooradian, M.J.; Ganguli, S.; Uppot, R.N.; Yamada, K.; Irani, Z.; Wehrenberg-Klee, E.P.; Zubiri, L.; Reyn-olds, K.L.; Arellano, R.S.; et al. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J. Vasc. Interv. Radiol. 2021, 32, 187–195. [Google Scholar] [CrossRef] [PubMed]
- Filippi, L.; Schillaci, O.; Cianni, R.; Bagni, O. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncol. 2018, 14, 809–818. [Google Scholar] [CrossRef] [PubMed]
- Sangro, B.; Gil-Alzugaray, B.; Rodriguez, J.; Sola, I.; Martinez-Cuesta, A.; Viudez, A.; Chopitea, A.; Iñarrairaegui, M.; Arbizu, J.; Bilbao, J.I. Liver disease induced by radioembolization of liver tumors: Description and possible risk factors. Cancer 2008, 112, 1538–1546. [Google Scholar] [CrossRef]
- Braat, M.N.; van Erpecum, K.J.; Zonnenberg, B.A.; van den Bosch, M.A.; Lam, M.G. Radioembolization-induced liver disease: A systematic review. Eur. J. Gastroenterol. Hepatol. 2017, 29, 144–152. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, A.S.; McNeillie, P.; Dezarn, W.A.; Nutting, C.; Sangro, B.; Wertman, D.; Garafalo, M.; Liu, D.; Coldwell, D.; Savin, M.; et al. Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors. Int. J. Radiat. Oncol. 2009, 74, 1494–1500. [Google Scholar] [CrossRef] [PubMed]
- Seidensticker, R.; Seidensticker, M.; Damm, R.; Mohnike, K.; Schütte, K.; Malfertheiner, P.; Van Buskirk, M.; Pech, M.; Amthauer, H.; Ricke, J. Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach. Cardiovasc. Interv. Radiol. 2012, 35, 1109–1118. [Google Scholar] [CrossRef]
- Badar, W.; Van Ha, T.; Zangan, S.; Navuluri, R.; Pillai, A.; Baker, T.; Dalag, L.; Han, R.; Ahmed, O. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br. J. Radiol. 2021, 94, 20200752. [Google Scholar] [CrossRef]
- Walrand, S.; Chiesa, C.; Gabina, P.M.; Chouin, N.; Gear, J.; Stokke, C.; Bernhardt, P.; Gleisner, K.S.; Strigari, L.; Konijnenberg, M.; et al. Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J. Vasc. Interv. Radiol. 2019, 30, 2047–2048. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Proietti, I.; Skroza, N.; Filippi, L.; Bernardini, N.; Mambrin, A.; Tolino, E.; Rossi, G.; Marchesiello, A.; Marraffa, F.; Volpe, S.; et al. Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy. Life 2021, 11, 692. https://doi.org/10.3390/life11070692
Proietti I, Skroza N, Filippi L, Bernardini N, Mambrin A, Tolino E, Rossi G, Marchesiello A, Marraffa F, Volpe S, et al. Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy. Life. 2021; 11(7):692. https://doi.org/10.3390/life11070692
Chicago/Turabian StyleProietti, Ilaria, Nevena Skroza, Luca Filippi, Nicoletta Bernardini, Alessandra Mambrin, Ersilia Tolino, Giovanni Rossi, Anna Marchesiello, Federica Marraffa, Salvatore Volpe, and et al. 2021. "Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy" Life 11, no. 7: 692. https://doi.org/10.3390/life11070692